Table 3. Characteristic of randomized controlled trials included.
Reference | Study Design | No. of Subjects | Population | Age | drug | dosing | Outcomes | Follow-up | Exacerbation definition |
---|---|---|---|---|---|---|---|---|---|
FitzGerald J M 2016[37] | multi-center, double-blind parallel | 1205 | severe,uncontrolled, eosinophilic asthma | 12–75 | Benralizumab | Fourteen SC doses of 30mg or Eight SC doses of 30mg or placebo for 56 weeks | Asthma exacerbations; FEV1; ACQ-6; AQLQ | 56 weeks | An asthma exacerbation was defined as a worsening of asthma that led to one of the following: (1) use of systemic corticosteroids for 3 days or more or a temporary increase in a stable, background dosage of oral corticosteroids; (2) an emergency department or urgent care visit (<24 h) due to asthma that required systemic corticosteroids; or (3) an inpatient admission to hospital (≥24 h) due to asthma. |
FEV1, forced expiratory volume in 1 second; PEF, peak expiratory flow; histamine PC20, provocative concentration of histamine required to cause a 20% fall in FEV1; JACQ, Juniper Asthma Control Questionnaire; AQLQ, the Asthma Quality of Life Questionnaire; ACQ, Asthma Control Questionnaire; FeNO, fraction of exhaled nitric oxide; SABAs: short-acting beta-agonists (SABAs); SC: subcutaneous injections; IV, intravenous; ICS, inhaled corticosteroid; OCS, oral corticosteroid; NM: not mentioned